News

VIPC Awards Commonwealth Commercialization Fund Grant to Carilion Medical Center

Carilion Medical Center is a non-profit healthcare organization based in Roanoke, Va. The principal investigator for this grant is Dr. Umar Sofi, MD, is a practicing pulmonologist and an Associate Professor of Medicine at the Virginia Tech Carilion School of Medicine in Roanoke, Va. The CCF-funded project grew from Dr. Sofi’s frustration with currently available oxygen delivery systems, which are time-consuming for healthcare providers and do not respond to a patient’s ever-changing oxygen needs. In response to this need, Dr. Sofi assembled a cross-functional team of experts from Carilion Clinic and Virginia Polytechnic Institute and State University (Virginia Tech) to design and build an innovative oxygen delivery system. The flow-regulated nasal oxygen delivery system (FRNDS) offers significant improvements compared to legacy oxygen delivery systems.

“We appreciate the CCF grant from VIPC for FRNDS,” said Dr. Umar Sofi. “There is currently no device for high-flow oxygen that can adapt to a patient’s respiratory needs. We are developing FRNDS to overcome those hurdles by measuring a patient’s inspiratory flow to improve patient outcomes.”

“We are pleased to award a CCF grant to support Dr. Sofi’s commercialization efforts,” said Hina Mehta, PhD, VIPC’s Director for University Programs. “VIPC’s CCF higher education grant program plays an important role in getting funding to Virginia’s entrepreneurially-minded university researchers as they work to take innovations from lab to market. Dr. Sofi’s research has identified a significant unmet need in the respiratory care field, and he is leading a top-notch team that is committed to building and demonstrating a working prototype of FRNDS.”

CCF accepts applications and awards funding on a rolling basis to Virginia’s small businesses and university-based innovators. The CCF Higher education grant program seeks to fund high-potential Virginia-based academic research teams that are developing technologies with strong commercial potential. The grants support early technology and market validation efforts such as customer discovery, market research, business model validation, development of prototypes or a minimum viable product (MVP), customer pilots, intellectual property protection, team development, and more. For more information on funding opportunities and eligibility requirements, or to apply, visit: www.VirginiaIPC.org

Recent News

03/19/2026

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a new genetic testing program with Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a commercial-stage biopharmaceutical company focused on bringing life-changing therapeutics to people living with rare diseases. The Niemann-Pick Disease type C (NPC) Sponsored Genetic Testing

03/18/2026

Phlow Corp. Appoints Dawn Von Rohr as Chief Operating Officer to Advance Domestic Pharmaceutical Manufacturing

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that Dawn Von Rohr has been appointed Chief Operating Officer (COO). Von Rohr will oversee Phlow’s operations, manufacturing execution, and strategic growth initiatives as the company continues expanding its advanced pharmaceutical development and manufacturing infrastructure in the United States to

03/17/2026

W&M Undergrads expand the chemical toolbox for cancer drugs

Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from unwanted side effects and limited efficacy. In a recent Bioconjugate Chemistry publication, William & Mary researchers designed an antibody-drug conjugate (ADC) with the potential to improve the potency and decrease the cost of currently approved cancer drugs. Like